You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(01.27)︱建業新生活年度純利預增逾八成;藥明生物年度淨利預增超65%
格隆匯 01-27 23:13

【財務數據】

金輝控股(09993.HK)中期淨利潤達10.46億元

寶積資本(08168.HK)一季度由盈轉虧91.4萬港元

【業績預吿】

泰格醫藥(03347.HK)年度純利預增100%至115%

卓越商企服務(06989.HK)預計年度純利同比增長75%

建業新生活(09983.HK)預計年度純利增長不少於80%

神州控股(00861.HK)預計年度純利大幅增長逾80%

上海石油化工股份(00338.HK)業績預吿:2020年淨利同比減少69%-74%

藥明生物(02269.HK)年度淨利預增超65%

黛麗斯國際(00333.HK)中期預盈不少於2540萬港元

中國新城鎮(01278.HK)預計年度由盈轉虧2.45億元

堅寶國際(00675.HK):預計年度純利大幅增長約300%

【營運數據】

大悦城地產(00207.HK)2020年合同銷售201.22億元 同比增長67.32%

華電國際電力股份(01071.HK)2020年累計上網電量1.95億兆瓦時 同比降低3.42%

上海石油化工股份(00338.HK)2020年柴油銷量398.21萬噸

MONGOLIAN MINING(00975.HK)2020年全年原煤開採量770萬噸

【復牌停牌】

銀合控股(08260.HK):公司股份將於明日復牌

【股本重組】

民生國際(00938.HK)擬"5合1"進行股份合併

基石金融(08112.HK)擬"1供4"進行供股 淨籌3004萬港元

思捷環球(00330.HK)擬"2供1"進行供股 淨籌不少於約6.89億港元

【併購出售】

中國智慧能源(01004.HK)擬3.5億元出售金昌迪生全部股權

中遠海運港口(01199.HK)擬1.4億美元收購RSGT約20%股權

麗珠醫藥(01513.HK):麗珠生物擬3944.57萬元收購麗珠香港100%股權

【投資與運營】

先健科技(01302.HK)主動脈覆膜支架系統進入創新醫療器械特別審查程序

君實生物(01877.HK)抗TIGIT單抗JS006注射液獲得藥物臨牀試驗批准通知書

四環醫藥(00460.HK)完成收購吉林遨通和吉林佳輝股份 將極大加強CDMO服務能力

帝國集團環球控股(00776.HK):NVXQF隊於2020年度和平精英PMGC全球總決賽奪冠

國微控股(02239.HK)擬攜手深圳天使投資成立基金 投資深圳經營創新技術產業初期公司

平安好醫生(01833.HK):聚焦醫療+健康 “平安好醫生”APP正式更名為“平安健康”

建鵬控股(01722.HK)獲授建築工程合約 總額約4.358億澳門元

泰和小貸(01915.HK)出資8000萬元參與設立合資公司 聚焦人工智能及物聯網業務

復星醫藥(02196.HK):注射用FN-1501獲藥品臨牀試驗批准

重慶機電(02722.HK)參股公司有研粉末獲批於上交所科創板註冊

匯盈控股(00821.HK)擬投資水通道蛋白水業務

洪橋集團(08137.HK)與新吉奧訂立戰略合作協議

【回購註銷】

DYNAM JAPAN(06889.HK)1月27日耗資227.78萬港元回購29.36萬股

艾德韋宣集團(09919.HK)1月27日註銷455.2萬股回購股份

【股權激勵】

星星地產(01560.HK)授出2725萬份購股權

BC科技集團(00863.HK)授出350萬份購股權及216萬股獎勵股份

【債務融資】

有線寬頻(01097.HK)擬向控股股東發行2億港元可換股證券

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account